How effective is cabozantinib in treating kidney cancer?

Cabozantinib (Cabozantinib), as a multi-target tyrosine kinase inhibitor, has shown significant efficacy in the treatment of renal cell carcinoma (kidney cancer). Studies in clinical trials and in practice have shown that cabozantinib has significant antitumor activity and survival benefits in patients with advanced or metastatic kidney cancer. It can slow down tumor progression and metastasis by inhibiting tumor cell growth and angiogenesis. Cabozantinib is already approved for the treatment of patients with metastatic renal cell carcinoma, particularly those whose disease has progressed after prior treatment with other therapies. Not only can it prolong patient survival, it can also significantly slow down the risk of disease progression, thereby providing patients with a better quality of life.